Benzothienyl-disubstituted pyrrolotriazines and their use as inhibitors of FGFR kinase

A compound of formula (I) ** ** Formula wherein R1 is hydrogen, chlorine, methyl or methoxy, R2 is hydrogen or methoxy, provided that at least one of R1 and R2 is different from hydrogen, G1 represents chlorine , (C1-C4) alkoxycarbonyl (C1-C4), aza-heteroaryl group members or -CH2 OR3, -CH2-NR4R5 or -C (> = O) -NR4R6, wherein R3 is hydrogen, (C1-C4) -alkyl or (C3-C6) or phenyl, (i) said (C1-C4) is optionally substituted with hydroxy, (C1-C4), hydroxycarbonyl, alkoxycarbonyl (C1-C4), amino, aminocarbonyl , mono- (C1-C4) -alkyl-aminocarbonyl, di-alkylaminocarbonyl (C1-C4) - alkyl, (C3-C6) or up to three fluorine atom, and (ii) said (C3-C6) optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4), hydroxy and amino, and (iii) said phenyl is optionally substituted with one or two substituents independently selected from the group with sists of fluorine, chlorine, bromine, cyano, trifluoromethyl, trifluoromethoxy, (C1-C4) alkoxy (C1-C4), R4 is hydrogen or (C1-C4), R5 is hydrogen, (C1-C4), alkylcarbonyl (C1-C4) alkyl, (C3-C6) or heterocycloalkyl 4 to 6 members, wherein (i) said (C1-C4) is optionally substituted with hydroxy, (C1-C4), hydroxycarbonyl, alkoxycarbonyl ( C1-C4) aminocarbonyl, mono- (C1-C4) -alkyl-aminocarbonyl, di-alkylaminocarbonyl (C1-C4) -alkyl or (C3-C6), and (ii) said (C3-C6) optionally substituted with one or two independently selected substituents from the group consisting of (C1-C4), hydroxy and amino, and (iii) said heterocycloalkyl of 4 to 6 membered is optionally substituted with one or two independently selected substituents from the group consisting of alkyl ( C1-C4) alkyl, hydroxy, oxo and amino, R6 is hydrogen, (C1-C4) alkyl, (C3-C6) heterocycloalkyl or 4 to 6 members, and n wherein (i) said (C1-C4) is optionally substituted with hydroxy, (C1-C4), hydroxycarbonyl, alkoxycarbonyl (C1-C4), amino, aminocarbonyl, mono- (C1-C4) -alkyl-aminocarbonyl, di-alkylaminocarbonyl (C1-C4) -alkyl or (C3-C6), and (ii) said (C3-C6) optionally substituted with one or two independently selected substituents from the group consisting of (C1-C4) hydroxy and amino, and (iii) said heterocycloalkyl of 4 to 6 membered is optionally substituted with one or two independently selected substituents from the group consisting of (C1-C4) alkyl, hydroxy, oxo and amino, or R4 and R5, or R4 and R6, respectively, are bonded and taken together with the nitrogen atom to which they are attached form a monocyclic heterocycloalkyl ring, saturated 4 to 7 members which may contain a second ring heteroatom selected from N (R7) and O, and which may be substituted on the ring carbon atoms c on one or two substituents independently selected from the group consisting of (C1-C4), oxo, hydroxy, amino and aminocarbonyl, and wherein R7 is hydrogen, (C1-C4), formyl or alkylcarbonyl (C1-C4), and G2 represents chlorine, cyano, (C1-C4) or -CR8AR8B-OH, -CH2-NR9R10, -C (> = O) -NR11R12 or -CH2-OR15, R8A and R8B where group are independently selected from group consisting of hydrogen, (C1-C4), cyclopropyl and cyclobutyl, R9 is hydrogen or (C1-C4), R10 is hydrogen, (C1-C4) alkyl, (C1-C4) alkyl, (C3- C6) heterocycloalkyl or 4 to 6 members, wherein (i) said (C1-C4) is optionally substituted with hydroxy, amino, aminocarbonyl, mono- (C1-C4) -alkylaminocarbonyl or di-alkylaminocarbonyl (C1-C4) and (ii) said (C3-C6) optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4), hydroxy and amino, and (iii) said heterocycloalkyl 4 to 6-membered is optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4) alkyl, hydroxy, oxo and amino, R11 is hydrogen or (C1-C4), R12 is hydrogen, (C1-C4) alkyl, (C3-C6) or heterocycloalkyl 4 to 6 members, wherein (i) said (C1-C4) is optionally substituted with hydroxy, amino, aminocarbonyl, mono- (C1-C4) - alkylaminocarbonyl or di-alkylaminocarbonyl (C1-C4), and (ii) said (C3-C6) optionally substituted with one or two substituents independently selected from the group consisting of (C1-C4), hydroxy and amino, and (iii) said heterocycloalkyl of 4 to 6 membered is optionally substituted with one or two independently selected substituents from the group consisting of (C1-C4) alkyl, hydroxy, oxo and amino, or R9 and R10, or R11 and R12, respectively, they are bonded and taken together with the nitrogen atom to c ual are attached form a monocyclic heterocycloalkyl ring, saturated 4 to 7 members which may contain a second ring heteroatom selected from N (R13), O, S and S (O) 2 and which may be substituted at the carbon atoms ring with up to three substituents independently selected from the group consisting of fluorine, (C1-C4), oxo, hydroxy, amino and aminocarbonyl, and wherein R13 is hydrogen, (C1-C4) -alkyl or (C3 C6 alkyl), formyl or alkylcarbonyl (C1-C4), and R15 is (C1-C4), provided that G1 is not chlorine when G2 is chlorine or cyano, or a salt, hydrate and / or solvate it acceptable for pharmaceutical use.